According to the Zhitong Finance App, Kanglong Chemical (03759) announced that it expects to obtain operating income of 7.47 billion yuan to 7.66 billion yuan in the 2026 semi-year, an increase of 16% to 19% over the same period of the previous year; net profit attributable to shareholders of listed companies was 729 million yuan to 772 million yuan, an increase of 4% to 10% over the same period last year.

In the first half of 2026, along with the continuous expansion of the company's strategic customers and the continuous advancement of the small-molecule CDMO service project pipeline, the company's new orders increased by more than 30% year-on-year; among them, new orders for laboratory services increased by more than 20% year-on-year, and new orders for small-molecule CDMO services increased by more than 50% year-on-year. The company continues to increase talent introduction efforts and expand R&D and production service teams to meet rapidly growing business needs.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.